Highlights from 2018

Following on from our successful 2018 launch, we’ll be coming back to the Pacific Northwest in October 2019 with 2 more days of insight, case studies and best practice for clinical trial management.

As the local pharma industry develops so do we, we’ll bring you a programme which reflects the current changes in the Pacific Northwest sector. Whether it’s regulatory change, new political climate or transformation in the local industry we’ll create a programme which suits your needs.

Key sessions from our 2018 event include:

KEYNOTE: Home Advantage: Assessing the Pacific Northwest’s competitive landscape to underpin and sustain your competitive advantage

This keynote session was delivered first thing on Day 1 by Stephen Shrewbury, who is Chief Medical Officer at Impel NeuroPharma. Stephend discussed in-depth how to succeed in such a competitive environment.

PANEL DISCUSSION: Comparing international with local clinical trials to assess optimum studies

Our Day 1 panel discussion was moderated by our chair, Darrell J. Panich at RepliCel Life Sciences, and the panellists debating the topic included;

• Stephen Shrewbury, MD, Chief Medical Officer, Impel NeuroPharma Inc
• Jim Pankovich, Vice President, Clinical Operations & Drug Development, Qu Biologics Ltd.
• Heidi Biagi, Director, Clinical Operations, Aquinox Pharmaceuticals, Inc

Quality vs Costs: Exploring needs to strike optimal balance between quality and cost of outsourcing clinical trials to achieve first-rate business strategies

This presentation session was given by Theresa Deisher (CEO of AVM biotechnology), who discussed budgeting considerations in your clinical trials. She gave her view on quality vs costs- what’s yours?

REGULATORY UPDATE

Assessing the regulatory landscape and considerations in global clinical trials- what are the key aspects you need to be thinking about?

Finally, our regulatory keynote presentation was delivered by

Jill Herendeen, who is Senior Director of Regulatory Affairs at Pharmacyclics.